Precision cancer drug developer Novellus boosted its funding total to $75.5m with a round featuring SR One and Novartis Venture Fund.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.

Unnamed corporates have provided capital for Panlin’s $148m fund that will focus on healthcare, digital transformation and smart hardware.

Tal Heppenstall will stand down as president of UPMC Enterprises to be replaced by Jeanne Cunicelli, promoted from executive vice-president.

K Wah Group’s subsidiary has taken part in the tumour therapy and drug developer’s $29.3m round, which came a year after its $28m series B round.

Global University Venturing: Covid-19 remains a threat but universities are at the forefront of fighting back

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

The testing services provider hiked its overall funding to more than $68m in a round backed by Alibaba Hong Kong Entrepreneurs Fund.

Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.